Anticoagulant and Antiplatelet Use Not Associated with Improvement in Severe Outcomes in COVID-19 Patients

Introduction: SARS-CoV-2 coronavirus (COVID-19) associated coagulopathy leads to higher morbidity and mortality. It is unclear if anticoagulants or antiplatelets in patients with COVID-19 influences disease severity. We report outcomes of COVID-19 patients prescribed anticoagulants or antiplatelets...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Gwendolyn, Dusendang, Jennifer R, Schmittdiel, Julie, Kavecansky, Juraj, Tavakoli, Jahan, Pai, Ashok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2020
Materias:
904.Outcomes Research-Non-Malignant Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330166/
http://dx.doi.org/10.1182/blood-2020-134254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330166/
http://dx.doi.org/10.1182/blood-2020-134254

Ejemplares similares